Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome (RECONNECT)

May 6, 2024 updated by: Zynerba Pharmaceuticals, Inc.

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults With Fragile X Syndrome - RECONNECT

This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of Cannabidiol administered as ZYN002 for the treatment of children, adolescent, and young adult patients with Fragile X Syndrome (FXS). Eligible participants will participate in up to an 18-week treatment period, where all participants will receive placebo or active study drug. Patients ages 3 to < 23 years will be eligible to participate.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of ZYN002, a pharmaceutically manufactured cannabidiol, formulated as a clear gel that can be applied to the skin (called transdermal delivery), in children, adolescents, and young adults with FXS. 204 male and female patients, ages 3 to < 23 years, will be randomized 1:1 to either trial drug or placebo and will undergo an 18-week treatment period. Randomization will be stratified by gender, methylation status and weight. The study will be comprised of a Screening visit and a combination of seven visits both onsite (face-to-face) and virtual. The assignment of study drug or placebo will be done by a computer-generated system and neither the study doctor, participant or their caregivers will know which treatment is being given to them. The dose of the treatment will depend on the weight of the participants. If the participants weigh less than or equal to 30 kg, they will receive 2 sachets of the gel per day (1 sachet approximately every 12 hours). If the participant weighs more than 30 kg but less than or equal to 50 kg, they will receive 4 sachets of gel per day (2 sachets approximately every 12 hours). Participants who weigh more than 50 kg will receive 6 sachets of gel per day (3 sachets approximately every 12 hours). Parents/ caregivers will be instructed on proper application of the gel. The gel will be applied to clean, dry, intact skin of the upper arms/ shoulders.

Blood samples will be collected for safety analysis of ZYN002. An independent analytical laboratory will also perform CGG repeat and methylation status analyses. Additionally, the parents/caregivers and study doctor will be asked to complete some questionnaires for efficacy and safety assessment.

Study Type

Interventional

Enrollment (Estimated)

204

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Australia
    • New South Wales
      • Sydney, New South Wales, Australia, 2145
    • Queensland
      • Brisbane, Queensland, Australia, 4101
        • Recruiting
        • Lady Cilento Children's Hospital - South Brisbane
        • Contact:
        • Principal Investigator:
          • Honey Heussler, MD
    • South Australia
      • Bedford Park, South Australia, Australia, 5042
        • Recruiting
        • Flinders Medical Centre
        • Contact:
        • Principal Investigator:
          • Dylan Mordaunt, MD
    • Victoria
      • Melbourne, Victoria, Australia, 3161
  • Ireland
      • Dublin, Ireland
        • Recruiting
        • Wellcome HRB Clinical Research Facility
        • Contact:
          • Aoife Mahony, MB Bch BAO
        • Principal Investigator:
          • Aoife Mahony, MB Bch BAO
  • United Kingdom
      • Edinburgh, United Kingdom
        • Recruiting
        • University of Edinburgh
        • Contact:
          • Andrew Stanfield, MD
        • Principal Investigator:
          • Andrew Stanfield, MD
      • Leicester, United Kingdom
        • Recruiting
        • Leicester Clinical Research
        • Contact:
          • Julian Barwell, MD
        • Principal Investigator:
          • Julian Barwell, MD
      • London, United Kingdom
        • Recruiting
        • King's College
        • Contact:
          • Andre Strydom
        • Principal Investigator:
          • Andre Strydom, MD
      • Manchester, United Kingdom
        • Recruiting
        • Manchester University NHS Foundation Trust
        • Contact:
        • Principal Investigator:
          • Catherine Breen, MD
  • United States
    • California
      • Culver City, California, United States, 90230
        • Recruiting
        • Science 37
        • Principal Investigator:
          • David Kudrow, MD
        • Contact:
          • David Kudrow, MD
      • Orange, California, United States, 92868
        • Recruiting
        • Thompson Autism Center CHOC
        • Principal Investigator:
          • Sailaja Golla, MD
        • Contact:
          • Sailaja Golla, MD
      • Sacramento, California, United States, 95817
        • Recruiting
        • UC Davis Health System, MIND Institute
        • Contact:
        • Principal Investigator:
          • Randi Hagerman, MD
    • District of Columbia
      • Washington, District of Columbia, United States, 20010
        • Recruiting
        • Children's National Medical Center
        • Contact:
        • Principal Investigator:
          • Sinan Turnacioglu, MD
    • Florida
      • Miami, Florida, United States, 33136
        • Recruiting
        • University of Miami
        • Contact:
        • Principal Investigator:
          • Barbara Coffey, MD
    • Georgia
      • Atlanta, Georgia, United States, 30318
    • Illinois
      • Chicago, Illinois, United States, 60612
        • Recruiting
        • Rush University Medical Center
        • Principal Investigator:
          • Elizabeth Berry-Kravis, MD
        • Contact:
    • Maryland
      • Baltimore, Maryland, United States, 21205
        • Recruiting
        • Kennedy Krieger Institute
        • Contact:
        • Principal Investigator:
          • Dejan Budimirovic, MD
    • Massachusetts
    • Minnesota
      • Minneapolis, Minnesota, United States, 55454
        • Recruiting
        • University of Minnesota Fragile X Clinic (Voyager Clinic)
        • Contact:
        • Principal Investigator:
          • Amy Esler, PhD
    • Mississippi
      • Jackson, Mississippi, United States, 39216
        • Recruiting
        • University of Mississippi
        • Contact:
        • Principal Investigator:
          • John Ingram, MD
    • New York
      • New York, New York, United States, 10029
        • Recruiting
        • The Fragile X Spectrum Disorder Clinic at Icahn School of Medicine at Mount Sinai, Division of Medical Genetics
        • Contact:
        • Principal Investigator:
          • Reymundo Lozano, MD
    • North Carolina
      • Chapel Hill, North Carolina, United States, 27510
        • Recruiting
        • University of North Carolina
        • Contact:
        • Principal Investigator:
          • Jamie Capal, MD
    • Ohio
      • Cincinnati, Ohio, United States, 45229
        • Recruiting
        • Cincinnati Children's Hospital Medical Center
        • Contact:
        • Principal Investigator:
          • Craig Erickson, MD
    • Oklahoma
      • Tulsa, Oklahoma, United States, 74136
        • Recruiting
        • Central States Research
        • Contact:
        • Principal Investigator:
          • Sarah Land, MD
    • Pennsylvania
      • Hershey, Pennsylvania, United States, 17033
        • Recruiting
        • Penn State Hershey Medical Center
        • Principal Investigator:
          • Patricia Gordon, MD
    • South Carolina
      • Greenville, South Carolina, United States, 29605
        • Recruiting
        • Greenwood Genetic Center
        • Contact:
        • Principal Investigator:
          • Carrie Buchanan, MD
    • Utah
      • Salt Lake City, Utah, United States, 84113
        • Recruiting
        • Primary Children's Hospital
        • Contact:
        • Principal Investigator:
          • Victoria Wilkins, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

3 years to 23 years (Child, Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Male or female children and adolescents aged 3 to < 23 years, at the time of Screening.
  • Patient resides with caregiver who will continue to provide consistent care throughout the study.
  • Judged by the Investigator to be in generally good health at Screening based upon the results of medical history, physical exam, 12-lead ECG and clinical laboratory test results. -Laboratory results outside the reference range must be documented as not clinically significant by both the Investigator and Sponsor.
  • Participants must have a diagnosis of FXS through molecular documentation of full mutation of the FMR1 gene documented through genetic testing at Screening.
  • Patients with a history of seizure disorders must currently be receiving treatment with a stable regimen of no more than two anti-seizure medications (ASMs) for the four weeks preceding study Screening; or must be seizure-free for one year if not currently receiving ASMs.
  • Patients taking psychoactive medication(s) should be on a stable regimen of not more than three such medications for at least fours weeks preceding Screening and must maintain that regimen throughout the study. Psychoactive medications include (but are not limited to) antipsychotics, antidepressants, anxiolytics, attention-deficit / hyperactivity disorder (ADHD) medications, and medications for sleep.
  • If patients are receiving non-pharmacological, behavioral and/or dietary interventions, they must be stable and have been doing so for three months prior to screening.
  • Patients have a body mass index between 12-30 kg/m2 (inclusive).
  • Females of childbearing potential must have a negative serum pregnancy test at the Screening Visit and a negative serum or urine pregnancy test at all designated visits.
  • Patients and parents/caregivers must be adequately informed of the nature and risks of the study and given written informed consent prior to Screening.
  • Patients and parents/caregivers agree to abide by all study restrictions and comply with all study procedures, and in the Investigator's opinion, are reliable and willing and able to comply with all protocol requirements and procedures.

Exclusion Criteria:

  • Females who are pregnant, nursing or planning a pregnancy; females of childbearing potential and male patients with a partner of childbearing potential who are unwilling or unable to use an acceptable method of contraception as outlined below for the duration of therapy and for three months after the last dose of study medication. Standard acceptable methods of contraception include abstinence (defined as refraining from heterosexual intercourse from screening to three months after the last dose of study medication) or the use of a highly effective method of contraception, including hormonal contraception, diaphragm, cervical cap, vaginal sponge, condom, spermicide, vasectomy, or intrauterine device. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject. Periodic abstinence (calendar, symptothermal, post-ovulation methods) is not an acceptable method of contraception.
  • Patient has transitioned to independent living or living in a residential facility such as a university setting or congregate care.
  • History of significant allergic condition, significant drug-related hypersensitivity, or allergic reaction to any compound or chemical class related to ZYN002 or its excipients.
  • Exposure to any investigational drug or device less than or equal to 30 days prior to Screening or at any time during the study.
  • Alanine aminotransferase (ALT), aspartate aminotransferase (AST) or total bilirubin levels greater than or equal to 2 times the upper limit of normal or alkaline phosphatase levels greater than or equal to 3 times the upper limit of normal.
  • Use of cannabis or any THC or CBD-containing product within 3 months of Screening Visit or during the study (aside from ZYN002).
  • Patient has a positive drug screen, including ethanol, cocaine, THC, barbiturates, amphetamines (unless prescribed), benzodiazepines (except midazolam or comparable administered for blood draws and ECG collection), and opiates.
  • Patient is using the following AEDs (medications for the treatment of seizures and/ or epilepsy): clobazam, phenobarbital, ethosuximide, felbamate, carbamazepine, phenytoin, or vigabatrin.
  • Patient is using a strong inhibitor/inducer of CYP3A4 or sensitive substrate of CYP3A4 including but not limited to the following medications: midazolam (except single doses administered for the purposes of obtaining blood samples and ECG's), oral ketoconazole, fluconazole, nefazadone, rifampin, alfentanil, alfuzosin, amiodarone, cyclosporine, dasatinib, docetaxol, eplerenone, ergotamine, everolimus, fentanyl, halofantrine, irinotecan, lapatinib, levomethadyl, lumefantrine, nilotinib, pimozide, quinidine, ranolazine, sirolimus, tacrolimus, temsirolimus, toremifene, tretinioin, vincristine, vinorelbine, St. John's Wort, and grapefruit Juice/products.
  • Patients may not be taking any benzodiazepines (except single doses administered for the purposes of obtaining blood samples and ECGs) at screening or throughout the study.
  • Patient is expected to initiate or change pharmacologic or non-pharmacologic interventions during the course of the study.
  • Patient has an advanced, severe, or unstable disease that may interfere with the study outcome evaluations.
  • Patient has acute or progressive neurological disease, psychosis, schizophrenia or any other psychiatric disorder or severe mental abnormalities (other than FXS) that are likely to require changes in drug therapy or interfere with the study objectives or ability to adhere to protocol requirements.
  • Patient has a positive result for the presence of HBsAg, HCV, or HIV antibodies.
  • Patient has known history of cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, cardiac conduction problems, exercise-related cardiac events including syncope and pre-syncope, risk factors for Torsades de pointes (TdP) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome), or other serious cardiac problems.
  • Any clinically significant condition or abnormal findings at the Screening Visit that would, in the opinion of the Investigator, preclude study participation or interfere with the evaluation of the study medication.
  • Any skin disease or condition including eczema, psoriasis, melanoma, acne, contact dermatitis, scarring, imperfections, lesions, tattoos, or discoloration that may affect treatment application, application site assessments or absorption of the trial drug.
  • History of treatment for, or evidence of, drug abuse within the past year.
  • Previous participation in a ZYN002 study (with the exception of patients who were screen failures in Study ZYN2-CL-016 and did not enter Study ZYN2-CL-017).
  • Patient responds "yes" to Question 4 or 5 on the C-SSRS (Children) during Screening or at any time on study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ZYN002 - transdermal gel
Pharmaceutically manufactured. Cannabidiol is formulated as a clear gel for transdermal delivery.
Drug: ZYN002 - transdermal gel
Pharmaceutically manufactured cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery)
Other Names:
  • cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery)
Placebo Comparator: Placebo transdermal gel
Placebo is formulated as a clear gel for transdermal delivery.
Drug: Placebo

Placebo formulated as a clear gel that can be applied to the skin (transdermal delivery)

Other Names:

Placebo Comparator Matching Placebo

Other Names:
  • Matching Placebo
  • Placebo Comparator

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Aberrant Behavior Checklist-Community Fragile X Factor Structure (ABC-C FXS) Pre-specified Subscale 1 score in patients with complete methylation (100%) of the FMR1 gene.
Time Frame: Change from Baseline to Week 18
The ABC-C FXS is a standard parent/caregiver reported behavioral outcome measure for use in developmental disability clinical trials
Change from Baseline to Week 18

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Aberrant Behavior Checklist-Community, Fragile X Factor Structure (ABC-C FXS) Pre-specified Subscale 2 in patients with complete methylation (100%) of the FMR1 gene.
Time Frame: Change from Baseline to Week 18
The ABC-C FXS is a standard parent/caregiver reported behavioral outcome measure for use in developmental disability clinical trials
Change from Baseline to Week 18
Change on the Caregiver Global Impression of Change (CaGI-C) for Pre-specified parameter among patients with complete methylation (100%) of the FMR1 gene.
Time Frame: Change from Baseline to Week 18
The CaGI-C global impression of change is a 7-point Likert scale designed to measure behavioral symptomatic change at a specific time compared to baseline.
Change from Baseline to Week 18
Clinical Global Impression- Improvement (CGI-I) scale among patients with complete methylation (100%) of the FMR1 gene.
Time Frame: Change from Baseline to Week 18
The CGI-I global improvement item is a 7-point Likert scale to rate the behavioral change in a child at a specified time compared to baseline.
Change from Baseline to Week 18
Change in ABC-C FXS pre-specified Subscale 1 among all randomized patients (complete and partial methylation of the FMR1 gene).
Time Frame: Change from Baseline to Week 18
The ABC-C FXS is a standard parent/caregiver reported behavioral outcome measure for use in developmental disability clinical trials
Change from Baseline to Week 18
Number of patients with adverse events
Time Frame: Day 1, Week 2, Week 4, Week 6, Week 10, Week 14, Week 18 and through 4-week post-dose telephone follow-up
Collection of adverse events
Day 1, Week 2, Week 4, Week 6, Week 10, Week 14, Week 18 and through 4-week post-dose telephone follow-up
Number of participants with abnormal physical and neurological exams
Time Frame: Screening, Day 1 and Week 18
Physical and neurological exams
Screening, Day 1 and Week 18
Number of participants with abnormal clinical laboratory results
Time Frame: Screening, Week 10 and Week 18
Laboratory tests and urinalysis
Screening, Week 10 and Week 18
Number of participants with abnormal vital sign results
Time Frame: Screening, Day 1, Week 2 and Week 18
Vital sign measurements (blood pressure, heart rate, respiratory rate and temperature)
Screening, Day 1, Week 2 and Week 18
Number of participants with abnormal ECG
Time Frame: Screening and Week 18
12-lead ECG
Screening and Week 18
Withdrawal characteristics of ZYN002 using the Penn Physician Withdrawal Checklist
Time Frame: Week 18 and 4-week post last dose
Penn Physician Withdrawal Checklist
Week 18 and 4-week post last dose
Skin tolerability as assessed using daily skin diary
Time Frame: Daily from Day 1 through Week 18
Daily skin irritation diary
Daily from Day 1 through Week 18

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Zynerba Pharmaceuticals, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 13, 2021

Primary Completion (Estimated)

May 1, 2025

Study Completion (Estimated)

May 1, 2025

Study Registration Dates

First Submitted

July 20, 2021

First Submitted That Met QC Criteria

July 26, 2021

First Posted (Actual)

July 27, 2021

Study Record Updates

Last Update Posted (Actual)

May 7, 2024

Last Update Submitted That Met QC Criteria

May 6, 2024

Last Verified

October 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ZYN2-CL-033

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fragile X Syndrome

Clinical Trials on ZYN002 - transdermal gel

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe